TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating today.
Ritu Baral has given her Buy rating due to a combination of factors that highlight Neurogene’s promising developments in their clinical trials and financial stability. The ongoing enrollment in the Phase 1/2 trial for their Rett syndrome treatment, ‘401, shows progress with an expanded age range, which could enhance the comprehensiveness of the clinical data. This expansion is expected to support a broad label for the treatment, potentially increasing its market applicability.
Furthermore, Neurogene’s financial position appears robust, with a cash runway projected to last into the second half of 2027. This financial stability, combined with the benign safety profile of their low-dose ‘401 treatment and the absence of any clinical holds, suggests strong regulatory support. These factors collectively contribute to the positive outlook and the Buy rating for Neurogene’s stock.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $46.00 price target.